?ReSync Bio is a drug discovery management platform built to manage the complexity of preclinical discovery campaigns from target selection to IND package. We've built a high throughput platform that hosts computational models, manages CRO/CDMO requests, and centralizes campaign data for sharing and model training - internal and external. We integrate with existing deployments of CDD, Dotmatics, Schrödinger LiveDesign, SpotFire, and more tools.
What is the problem?
Currently, tracking the lifecycle of a compound through the Design-Make-Test cycle from virtual design tools to synthesis to assay can require tens of different software tools, alongside difficult to search emails and spreadsheets. Scientists in biotech and pharma we've spoken to spend up to 10 hours a week just searching and organizing data coming from in-house labs, CROs, and AI tools. This leads to slow programs, decisions, and lost information.
What is their solution?
ReSync's solution is a centralized, collaborative platform that allows scientists, managers, CROs, and partners to view all parts of the drug discovery process in one platform. Starting with virtual design, ReSync serves as the hub for running AI generations and predictions - a single place for research teams to share models with scientists. As scientists evaluate and move into the experimental workflow, ReSync captures request and fulfillment requests across all labs - whether internal or outsourced to CROs. Finally, assay data is returned on the ReSync platform, allowing direct comparison to previous predictions and trends over time.
